Insulet Stock

Insulet Gross Profit

The Gross Profit of Insulet (PODD) as of Aug 21, 2026 is 1.94 B USD. In the previous year, Gross Profit was 1.45 B USD — a change of 34.18% (higher).

Gross Profit

1.94 BUSD

YoY

34.18%

Last updated:

Gross Profit of Insulet is 2026 1.94 B USD. Gross Profit of Insulet was 2025 1.45 B USD. It decreases by 34.18% higher compared to the previous year.

The Insulet Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2023
68.35 base
Jan 1, 2024
69.79 base
Jan 1, 2025
71.63 base
Jan 1, 2026 (e)
58.96 base
Jan 1, 2027 (e)
51.68 base
Jan 1, 2028 (e)
41.62 base
Jan 1, 2029 (e)
35.69 base
Jan 1, 2030 (e)
31.78 base
YEARGROSS MARGIN (%)
2030 est 31.78
2029 est 35.69
2028 est 41.62
2027 est 51.68
2026 est 58.96
2025 71.63
2024 69.79
2023 68.35
2022 61.72
2021 68.45
2020 64.39
2019 65.06
2018 65.65
2017 59.76
2016 57.52
2015 50.50
2014 49.63
2013 45.49
2012 43.68
2011 43.82
2010 45.09
2009 27.71
2008 -12.71
2007 -92.44
2006 -327.52
Access this data via the Eulerpool API

Insulet Revenue

Insulet Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.70 B USD
220.00 M USD
206.30 M USD
Jan 1, 2024
2.07 B USD
308.90 M USD
418.30 M USD
Jan 1, 2025
2.71 B USD
473.80 M USD
247.10 M USD
Jan 1, 2026 (e)
3.29 B USD
384.30 M USD
467.90 M USD
Jan 1, 2027 (e)
3.75 B USD
454.96 M USD
555.61 M USD
Jan 1, 2028 (e)
4.66 B USD
538.82 M USD
726.37 M USD
Jan 1, 2029 (e)
5.44 B USD
628.33 M USD
877.48 M USD
Jan 1, 2030 (e)
6.10 B USD
705.57 M USD
1.03 B USD

Insulet Margins

Insulet stock margins

The Insulet margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Insulet. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Insulet.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
68.35 %
12.96 %
12.16 %
Jan 1, 2024
69.79 %
14.91 %
20.19 %
Jan 1, 2025
71.63 %
17.50 %
9.12 %
Jan 1, 2026 (e)
71.63 %
11.68 %
14.22 %
Jan 1, 2027 (e)
71.63 %
12.12 %
14.80 %
Jan 1, 2028 (e)
71.63 %
11.56 %
15.58 %
Jan 1, 2029 (e)
71.63 %
11.56 %
16.14 %
Jan 1, 2030 (e)
71.63 %
11.56 %
16.89 %

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insulet stock

Gross Profit of Insulet is 1.94 B USD in 2026.

Gross Profit of Insulet changed from 1.45 B USD to 1.94 B USD, representing a 34.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Insulet since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Insulet historically and in real time.

Access this data via the Eulerpool API

Income Statement — Insulet

All Key Metrics — Insulet